Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies

Acta Pharmacologica Sinica

Volumn 25, Issue 7, 2004, Pages 950-958

  Ma, Xiao Hui ^a   Zhang, Xiao Yi ^a   Tan, Jian Jun ^a   Chen, Wei Zu ^a   Wang, Cun Xin ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

AutoDock; Comparative molecular field analysis; HIV integrase; Inhibitors; Quinolines

Indexed keywords

CARBOXYL GROUP; HYDROXYL GROUP; INTEGRASE INHIBITOR; MAGNESIUM; QUINOLINE DERIVATIVE; STYRYLQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG INHIBITION; DRUG STRUCTURE; ENZYME ACTIVE SITE; NONHUMAN; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BINDING SITES; DRUG DESIGN; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES;

EID: 3142676449     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Caliendo AM, Hirsch TN, Liu B, Pattabiraman N, Erickson JW. Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994; 18: 516-24.
2. Appelt K, Clare M, Pettit S, Michael SF, Swantsrom R, Moore MC, et al. Therapeutic approaches to HIV. Perspect Drug Discov Des 1993; 1: 123-8.
3. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-71.
4. Pommier Y, Neamati N. Inhibitors of human immunodeficiency virus integrase. Adv Virus Res 1999; 52: 427-58.
5. Pluymers W, De Clercq E, Debyser Z. HIV-1 integration as a target for antiretroviral therapy: a review. Curr Drug Targets Infect Disord 2001; 1: 133-49.
6. Pommier Y, Marchand C, Neamati N. Review retroviral integrase inhibitor year 2000: update and perspectives. Antiviral Res 2000; 47: 139-48.
7. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-50.
8. Young SD. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Curr Opin Drug Discov Devel 2001; 4: 402-10.
9. Jing N, Hogan ME. Structure-activity of tetrad-forming oligonucleotides as potent anti-HIV therapeutic drug. J Biol Chem 1998; 273: 34992-9.
10. Craigie R. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 2001; 276: 23213-6.
11. Mekouar K, Mouscadet JF, Desmaële D, Subra F, Leh H, Savoure D, et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J Med Chem 1998; 41: 2846-57.
12. Zouhiri F, Mouscadet JF, Mekouar K, Desmaële D, Savouré D, Leh H, et al. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J Med Chem 2000; 43: 1533-40.
13. Ouali M, Laboulais C, Leh H, Gill D, Desmaële D, Mekouar K, et al. Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. J Med Chem 2000; 43: 1949-57.
14. Makhija MT, Kulkarni VM. Design value analysis of HIV-1 integrase inhibitors. J Chem Inf Comput Sci 2001; 41: 1569-77.
15. Yuan H, Parrill AL. QSAR studies of HIV-1 integrase inhibition. Bioorg Med Chem 2002; 10: 4169-83.
16. Makhija MT, Kulkarni VM. QSAR of HIV-1 integrase inhibitors by genetic function approximation method. Bioorg Med Chem 2002; 10: 1483-97.
17. Makhija MT, Kulkarnl VM. Molecular electrostatic potentials as input for the aligment of HIV-1 integrase inhibitors in 3D QSAR. J Comput Aided Mol Des 2001; 15: 961-78.
18. Cramer RD, Patterson III DE, Bunce JD. Comparative molecular field analysis (CoMFA) 1 effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988; 110: 5959-67.
19. Sybyl [molecular modeling package], version 6.9, St Louis (MO): Tripos Associates; 2000.
20. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 1985; 107: 3902-9.
21. Bush BL, Nachbar RB Jr. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 1993; 7: 587-619.
22. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19: 1639-62.
23. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 1999; 96: 13040-3.
24. Bohm M, Stuzerbercher J, Kliebe G. Three-dimensional quantitative structure-activity relationship analysis using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor xa. J Med Chem 1999; 42: 458-77.
25. Debnath AK. Comparative molecular field analysis (CoMFA) of a series of symmetrical bis-benzamide cyclic urea derivatives as HIV-1 protease inhibitors. J Chem Inf Comput Sci 1998; 38: 761-7.
26. Timberlake C. Potentiometric and polargraphic study of copper catechol complexes. J Chem Sco 1957; 997: 4987-93.
27. Branch GEK, Yabroff DL. The anomalous strength of salicylic acid. J Am Chem Soc 1934; 56: 2568-70.
28. Bardez E, Devol I, Larrey B, Valeur B. Excited-state processes in 8-hydroxyquinoline: photoinduced tautomerization and solvation effects. J Phys Chem B 1997; 101: 7786-93.
29. Albert A, Phillips JN. Ionization constants of heterocyclic substances. Part II: Hydroxy derivatives of nitrogenous sixmembered ring compounds. J Chem Soc 1956; 264: 1294-304.
30. Buolamwini JK, Assefa H. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J Med Chem 2002; 45: 841-52.